Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery
Tuesday, August 02, 2022
Ipsen and AGV Discovery today announced that Ipsen has exercised its option to acquire exclusive worldwide rights to an investigational ERK inhibitor, discovered by AGV Discovery.
The decision follows the successful achievement of a key developmental milestone and is the result of a research collaboration and option agreement between the companies, established in September 2020.
“We were encouraged by the early pre-clinical data and are excited to support the ongoing development of this promising therapeutic candidate”, said Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development (REED) at Ipsen. “We look forward to advancing the science that we hope can one day deliver new, innovative treatments for cancer patients with high unmet needs across a range of different tumor types.”
Cédric BORIES, President, AGV Discovery commented, “I am happy and proud to officially extend our collaboration with Ipsen. It represents a great opportunity to demonstrate our capabilities and have our asset grow, under the guidance of this innovative pharmaceutical company”.
